World Bulk Paclitaxel Market to Reach 1,040 Kilograms by 2012, According to New Report by Global Industry Analysts

Share Article

Driven by innovations in new paclitaxel formulations, drug delivery technologies, emergence of new indications and patent expiries, the world bulk paclitaxel market is projected to reach 1,040 kilograms by the year 2012. The United States maintains a stranglehold over the global market with a 91% share estimated for the year 2008. Strong demand for anti-cancer drugs is expected to sustain the demand for bulk paclitaxel as an effective, and powerful pharmaceutical ingredient.

Bulk Paclitaxel: A Global Strategic Business Report

World bulk paclitaxel market stands enthused by the effervescent levels of research and development. With market participants injecting resources into developing unique paclitaxel formulations, emergence of new disease indications is expected to result in expanded market opportunities in the medium to long run. For instance, development of paclitaxel-coated coronary stents will help further improve the use and sales of paclitaxel. Research studies are presently concentrated around studying the efficacy of paclitaxel against multiple sclerosis, psoriasis, fungal and viral diseases and rheumatoid arthritis. With patent expiries leading to the influx of generic forms of paclitaxel, competition is expected to intensify and result in price reductions. To offset the impact of price erosions, manufacturers are expected to target orphan diseases where competition is less and innovate paclitaxel formulations unique to the treatment of these diseases. Innovations in paclitaxel extraction technologies are expected to strengthen the market's supply equation, and ensure a continuous supply of raw materials.

As stated by a recent report published by Global Industry Analysts, Inc., the world market for bulk paclitaxel was an estimated US$195 million in 2007. Growth in volume sales is expected to outstrip the growth in dollar sales, reflecting the trend of falling prices. In the United Sates, volume consumption is expected to rise by 10% over the period 2008 to 2012, while dollar sales are expected to rise by just 4.3% for the same period.

Leading global and regional players operating in the industry include Abraxis BioScience Inc, Bioxel Pharma Inc, Bristol-Myers Squibb Co, Indena SpA, Hospira Inc, Teva Pharmaceuticals USA Inc, IVAX Corporation, Bedford Laboratories, and Xechem International Inc.

The report titled "Bulk Paclitaxel: A Global Strategic Business Report" published by Global Industry Analysts, Inc., provides a comprehensive review of market trends, drivers, issues, challenges, and research and development activities. Richly annotated with authoritative, and unbiased commentaries, and hard-to-find statistical facts, the report provides unequivocal views on future potential while throwing light on the prevailing climate in key regional markets. Latent demand patterns for Bulk Paclitaxel are quantified for the United States, and Rest of World. Also provided in the report is an enumeration of recent mergers, acquisitions, and other strategic industry activities.

For more details about this research report, please visit

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press @
Web Site


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website